CA2377092A1 - Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek - Google Patents
Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek Download PDFInfo
- Publication number
- CA2377092A1 CA2377092A1 CA002377092A CA2377092A CA2377092A1 CA 2377092 A1 CA2377092 A1 CA 2377092A1 CA 002377092 A CA002377092 A CA 002377092A CA 2377092 A CA2377092 A CA 2377092A CA 2377092 A1 CA2377092 A1 CA 2377092A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- fluoro
- phenylamino
- iodo
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
L'invention concerne une méthode de traitement de la douleur chronique au moyen d'un composé de formule (I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14441899P | 1999-07-16 | 1999-07-16 | |
US60/144,418 | 1999-07-16 | ||
PCT/US2000/018345 WO2001005390A2 (fr) | 1999-07-16 | 2000-07-05 | Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2377092A1 true CA2377092A1 (fr) | 2001-01-25 |
Family
ID=22508500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002377092A Abandoned CA2377092A1 (fr) | 1999-07-16 | 2000-07-05 | Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1202731A2 (fr) |
JP (1) | JP2003504398A (fr) |
KR (1) | KR20020015376A (fr) |
CN (1) | CN1358094A (fr) |
AU (1) | AU6068600A (fr) |
CA (1) | CA2377092A1 (fr) |
CO (1) | CO5190704A1 (fr) |
HU (1) | HUP0202319A3 (fr) |
IL (1) | IL147150A0 (fr) |
PE (1) | PE20010546A1 (fr) |
PL (1) | PL352835A1 (fr) |
WO (1) | WO2001005390A2 (fr) |
ZA (1) | ZA200109906B (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR035971A1 (es) | 2001-05-16 | 2004-07-28 | Cephalon Inc | Metodos para el tratamiento y la prevencion del dolor |
WO2002102232A2 (fr) * | 2001-06-14 | 2002-12-27 | The Regents Of The University Of California | Nouvelle voie de signalisation destinee a la production de douleur inflammatoire et de neuropathie |
WO2003077855A2 (fr) * | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | Derives de benzimidazole n3 alkyles servant d'inhibiteurs de mek |
TWI350285B (en) | 2002-03-13 | 2011-10-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
GB0213383D0 (en) * | 2002-06-11 | 2002-07-24 | Cambridge Biotechnology Ltd | Therapeutic conditions |
US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
MXPA06000921A (es) | 2003-07-24 | 2006-03-30 | Warner Lambert Co | Derivados de benzamidazoles como inhibidores de mek. |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
NZ545864A (en) | 2003-09-22 | 2009-12-24 | S Bio Pte Ltd | Benzimidazole derivates: preparation and pharmaceutical applications |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
PL1689387T3 (pl) | 2003-11-19 | 2012-02-29 | Array Biopharma Inc | Bicykliczne inhibitory MEK i sposoby ich otrzymywania |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
EP2361905B1 (fr) | 2005-05-18 | 2013-03-06 | Array Biopharma Inc. | Inhibiteurs hétérocycliques de MEK et leurs utilisation |
KR20140000721A (ko) | 2005-06-23 | 2014-01-03 | 어레이 바이오파마 인크. | 벤즈이미다졸 화합물의 제조 방법 |
EP1934174B1 (fr) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives |
SI2049500T1 (sl) | 2006-07-06 | 2012-01-31 | Array Biopharma Inc | Ciklopenta (d) pirimidini kot AKT protein kinazni inhibitorji |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
CN101516891B (zh) | 2006-07-06 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶 |
CA2656566C (fr) | 2006-07-06 | 2014-06-17 | Array Biopharma Inc. | Dihydrofuro pyrimidines comme inhibiteurs de la proteine kinase akt |
US7999006B2 (en) | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
KR20150089099A (ko) | 2007-07-05 | 2015-08-04 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제로서의 피리미딜 시클로펜탄 |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
WO2009006569A1 (fr) | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes utilsés comme inhibiteurs de la protéine kinase akt |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
EP2231662B1 (fr) | 2007-12-19 | 2011-06-22 | Genentech, Inc. | 8-anilinoimidazopyridines et leur utilisation en tant qu'agents anticancéreux et/ou anti-inflammatoires |
PL2222675T3 (pl) | 2007-12-19 | 2014-02-28 | Genentech Inc | 5-anilinoimidazopirydyny i sposoby zastosowania |
JP5710269B2 (ja) | 2007-12-21 | 2015-04-30 | ジェネンテック, インコーポレイテッド | アザインドリジン類と使用方法 |
ES2401685T3 (es) | 2008-01-09 | 2013-04-23 | Array Biopharma, Inc. | Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT |
CN101932564B (zh) | 2008-01-09 | 2012-12-26 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷类 |
CN102137843A (zh) | 2008-07-01 | 2011-07-27 | 健泰科生物技术公司 | 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法 |
JP5746630B2 (ja) | 2008-11-10 | 2015-07-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換スルホンアミドフェノキシベンズアミド |
CN102656142A (zh) | 2009-10-21 | 2012-09-05 | 拜耳制药股份公司 | 取代的苯磺酰胺 |
EP2491016A1 (fr) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Benzosulfonamides substitués |
JP2013508320A (ja) | 2009-10-21 | 2013-03-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 置換されたハロフェノキシベンズアミド誘導体 |
US9045429B2 (en) | 2010-10-29 | 2015-06-02 | Bayer Intellectual Property Gmbh | Substituted phenoxypyridines |
EP2694073B1 (fr) | 2011-04-01 | 2018-08-08 | Genentech, Inc. | Combinaisons de inhibiteurs d'akt et mek pour le traitement du cancer |
KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Akt 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
ES2396764B1 (es) | 2011-11-02 | 2013-12-19 | Universidad Autónoma de Madrid | FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. |
ES2797123T3 (es) | 2011-12-21 | 2020-12-01 | Novira Therapeutics Inc | Agentes antivirales para la hepatitis B |
CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
NZ743463A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
MX2015004660A (es) | 2012-10-12 | 2015-08-07 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer. |
US9238627B2 (en) * | 2012-10-19 | 2016-01-19 | Array Biopharma, Inc. | Preparation of and formulation comprising a MEK inhibitor |
SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
AP2015008968A0 (en) | 2013-07-25 | 2015-12-31 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b |
DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
CN104774188B (zh) * | 2014-01-15 | 2019-10-11 | 江苏恒瑞医药股份有限公司 | 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
JP2022532526A (ja) | 2019-05-06 | 2022-07-15 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbv感染又はhbv誘導性疾患の処置において有用なアミド誘導体 |
CN110981819B (zh) * | 2019-12-24 | 2022-07-01 | 广西师范大学 | 一种喹喔啉类信号通路抑制剂及其制备方法和应用 |
CN114788867A (zh) * | 2022-04-24 | 2022-07-26 | 天津医科大学总医院 | Map2k1作为化疗后神经痛的治疗靶点的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
CZ20012498A3 (cs) * | 1999-01-13 | 2002-08-14 | Warner-Lambert Company | Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK |
-
2000
- 2000-07-05 KR KR1020027000589A patent/KR20020015376A/ko not_active Application Discontinuation
- 2000-07-05 WO PCT/US2000/018345 patent/WO2001005390A2/fr not_active Application Discontinuation
- 2000-07-05 CA CA002377092A patent/CA2377092A1/fr not_active Abandoned
- 2000-07-05 HU HU0202319A patent/HUP0202319A3/hu unknown
- 2000-07-05 EP EP00947013A patent/EP1202731A2/fr not_active Withdrawn
- 2000-07-05 PL PL00352835A patent/PL352835A1/xx unknown
- 2000-07-05 CN CN00809478A patent/CN1358094A/zh active Pending
- 2000-07-05 JP JP2001510447A patent/JP2003504398A/ja active Pending
- 2000-07-05 IL IL14715000A patent/IL147150A0/xx unknown
- 2000-07-05 AU AU60686/00A patent/AU6068600A/en not_active Abandoned
- 2000-07-14 CO CO00053306A patent/CO5190704A1/es not_active Application Discontinuation
- 2000-07-14 PE PE2000000704A patent/PE20010546A1/es not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109906A patent/ZA200109906B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001005390A2 (fr) | 2001-01-25 |
CO5190704A1 (es) | 2002-08-29 |
EP1202731A2 (fr) | 2002-05-08 |
ZA200109906B (en) | 2003-05-28 |
CN1358094A (zh) | 2002-07-10 |
AU6068600A (en) | 2001-02-05 |
IL147150A0 (en) | 2002-08-14 |
KR20020015376A (ko) | 2002-02-27 |
PE20010546A1 (es) | 2001-06-04 |
PL352835A1 (en) | 2003-09-08 |
HUP0202319A2 (en) | 2002-10-28 |
JP2003504398A (ja) | 2003-02-04 |
HUP0202319A3 (en) | 2004-12-28 |
WO2001005390A3 (fr) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2377092A1 (fr) | Methode de traitement de la douleur chronique au moyen d'inhibiteurs de mek | |
US6469004B1 (en) | Benzoheterocycles and their uses as MEK inhibitors | |
CA2377100A1 (fr) | Methode de traitement de la douleur chronique utilisant des inhibiteurs mek | |
US6506798B1 (en) | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors | |
US6455582B1 (en) | Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors | |
DE69926914T2 (de) | 1-heterozyklus-substituierte diarylaminen | |
US6750217B2 (en) | Benzenesulfonamide derivatives and their use as MEK inhibitors | |
DE60005688T2 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
JP2003504400A (ja) | Mek阻害剤を用いた慢性痛の治療方法 | |
US7030119B1 (en) | Method for treating chronic pain using MEK inhibitors | |
JP2000204079A (ja) | ジアリ―ルアミン | |
JP2004503535A (ja) | インドールおよびベンゾイミダゾール15−リポキシゲナーゼ阻害剤 | |
JP2000212141A (ja) | ジアリ―ルアミン | |
JP2000212157A (ja) | ジアリ―ルアミン | |
ZA200109909B (en) | Method for treating chronic pain using MEK inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |